Bacterial Co-Culture Composition for Reproducible Gut Microbiota Modeling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating gut dysbiosis, such as fecal microbiota transplantation, face challenges with safety, reproducibility, and scalability, and there is a need for bacterial compositions that closely resemble origin samples to effectively modulate microbial flora.
Innovation Solution
A method for producing a co-culture of bacteria grown in the presence of a particle, achieving at least 30% similarity and a bacterial load of at least 1·E4 per 1 gr particle, using anaerobic culturing conditions for less than 14 days, which can simulate an in-vitro microbial niche and evaluate the effect of compounds on bacterial populations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If fecal microbiota transplantation is used to treat gut dysbiosis, then the treatment effectiveness is improved, but safety risks and manufacturing scalability are worsened
Solution Approach 1:
The patent extracts and isolates specific beneficial bacterial strains from complex fecal samples, separating them from potential harmful components. This extraction process allows the therapeutic benefits to be retained while eliminating safety risks associated with unprocessed fecal material.
Solution Approach 2:
The patent creates standardized bacterial compositions that replicate the therapeutic effects of fecal microbiota transplantation without using actual fecal material. These standardized copies maintain treatment effectiveness while eliminating safety concerns and improving manufacturing scalability.
2Reliability
If fecal microbiota transplantation is used to treat gut dysbiosis, then the treatment effectiveness is improved, but manufacturing scalability and reproducibility are worsened
Solution Approach 1:
The patent segments the complex fecal microbiota into individual cultivable bacterial strains, allowing each strain to be produced, standardized, and controlled separately. This segmentation enables scalable manufacturing while maintaining the combined therapeutic effectiveness of the original microbiota.
Solution Approach 2:
The patent transforms the variable, complex composition of fecal samples into standardized bacterial compositions with controlled parameters including strain identity, concentration, and viability. This standardization enables reproducible manufacturing across different batches and facilities.
3Reliability
If complex microbial compositions are prepared to maintain high similarity to origin samples, then the effectiveness in modulating microbial flora is improved, but manufacturing complexity increases
Solution Approach 1:
The patent creates simplified copies of complex microbial communities using a defined set of cultivable bacterial strains. These compositions replicate the functional effects of origin samples while using standardized, easily manufacturable components, thereby reducing manufacturing complexity.
4Ease of manufacture
If the bacterial composition is simplified for easier manufacturing, then manufacturing scalability is improved, but similarity to origin sample and effectiveness are worsened
Solution Approach 1:
The patent applies local quality by selecting specific bacterial strains that are locally optimized for cultivability and stability while collectively maintaining the overall functional profile of the origin sample. Each strain is chosen for its specific contribution to the therapeutic effect, ensuring effectiveness despite simplification.
Data Source
AI summary
The present invention, in some embodiments, is directed to a method for producing a composition including a co-culture comprising a plurality of bacteria having a high similarity % to an origin sample and bacterial load.